Related Experiment Video

Updated: Jul 4, 2026

Characterization of Multi-subunit Protein Complexes of Human MxA Using Non-denaturing Polyacrylamide Gel-electrophoresis
08:55

Characterization of Multi-subunit Protein Complexes of Human MxA Using Non-denaturing Polyacrylamide Gel-electrophoresis

Published on: October 28, 2016

MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients

A Millonig1, A Dressel, D Bahner

  • 1Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

European Journal of Neurology
|June 14, 2008
PubMed
Abstract

Insights

Myxovirus resistance protein A (MxA) levels indicate biological response to interferon beta (IFNbeta) in primary progressive multiple sclerosis (PPMS). Higher MxA levels correlated with stable disease, suggesting MxA as a predictor of IFNbeta treatment effectiveness.

Area of Science:

  • Neuroimmunology
  • Biomarker Discovery
  • Multiple Sclerosis Therapeutics

Background:

  • Interferon beta (IFNbeta) shows limited efficacy in progressive multiple sclerosis (MS).
  • Non-response to IFNbeta may stem from individual biological variability.
  • Myxovirus resistance protein A (MxA) is a biomarker for IFNbeta bioactivity.

Purpose of the Study:

  • To investigate the correlation between MxA protein levels and clinical response to IFNbeta-1b in primary progressive MS (PPMS) patients.
  • To assess MxA as a potential indicator of treatment efficacy in PPMS.

Main Methods:

  • Twenty PPMS patients received subcutaneous IFNbeta-1b for one year.
  • MxA protein levels were measured in blood samples taken at multiple time points during treatment.
  • Clinical status was assessed using the Expanded Disability Status Scale (EDSS) and the Incapacity Status Scale (ISS).

Main Results:

  • Patients were stratified into stable (n=11) and progressing (n=9) groups based on ISS.
  • Mean area under the curve of log MxA levels was significantly higher in stable patients compared to progressing patients (10.87 vs. 5.99; P = 0.002).

Conclusions:

  • A robust biological response, indicated by higher MxA levels, may be associated with better clinical outcomes in PPMS patients treated with IFNbeta.
  • MxA levels could aid in the early identification of potential responders to IFNbeta therapy in future clinical studies.

More Related Videos

Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein09:39

Co-immunoprecipitation of the Mouse Mx1 Protein with the Influenza A Virus Nucleoprotein

Published on: April 21, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...